Share Price and Basic Stock Data
Last Updated: October 22, 2025, 5:28 am
| PEG Ratio | -5.70 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Aarey Drugs & Pharmaceuticals Ltd operates within the pharmaceuticals sector, with its current market capitalization standing at ₹233 Cr and a share price of ₹82. The company reported sales of ₹419 Cr for the fiscal year ending March 2023, which represented a decline from ₹493 Cr in March 2022. Notably, quarterly sales exhibited volatility, with a high of ₹210.35 Cr in March 2024, followed by a decrease to ₹108.10 Cr in March 2025. This fluctuation indicates challenges in maintaining stable revenue streams. The company’s operational performance, reflected in its Operating Profit Margin (OPM), has been relatively low, recorded at 1.67%. A significant aspect of the sales performance is the company’s ability to generate income, which has been inconsistent, as evidenced by its quarterly sales dropping to ₹50.96 Cr in June 2023 before partially recovering. Overall, while Aarey Drugs shows potential for revenue growth, its historical sales trends reveal a need for strategic adjustments to stabilize its revenue base.
Profitability and Efficiency Metrics
The profitability of Aarey Drugs is characterized by a low Return on Equity (ROE) of 2.96% and Return on Capital Employed (ROCE) of 6.38%, highlighting significant room for improvement in efficiency and capital utilization. The company’s Net Profit for the trailing twelve months stood at ₹4 Cr, translating to an Earnings Per Share (EPS) of ₹1.84 for March 2025. Notably, the Interest Coverage Ratio (ICR) is reported at 3.00x, indicating that the company can comfortably meet its interest obligations. However, the operating profits have been inconsistent, with quarterly figures showing a troubling negative operating profit of ₹1.44 Cr in March 2024. This inconsistency in profitability is further reflected in the fluctuating margins, where the Net Profit Margin stood at 0.84% for March 2025. The company’s ability to manage expenses effectively is crucial for enhancing profitability, as evidenced by the operating expenses consistently outpacing revenues during certain quarters.
Balance Sheet Strength and Financial Ratios
Aarey Drugs maintains a relatively strong balance sheet, with total reserves amounting to ₹110 Cr against borrowings of ₹35 Cr, reflecting a conservative leverage position. The Debt to Equity ratio is reported at 0.25, underlining a prudent approach to financing, which is favorable compared to industry norms. The liquidity position appears robust, with a Current Ratio of 2.20 and a Quick Ratio of 1.73, suggesting the company is well-positioned to meet its short-term obligations. The Cash Conversion Cycle (CCC) stood at 58 days, indicating a reasonable efficiency in managing working capital, though this is an increase from previous years. The Price to Book Value (P/BV) ratio is at 0.68x, indicating that the market values the company’s shares at a discount to its book value, which could signal potential undervaluation. However, the low ROE and ROCE figures suggest that while the balance sheet is strong, the company is not capitalizing on its assets effectively.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Aarey Drugs reveals a diversified ownership structure, with promoters holding 44.80% of the equity, a decline from previous periods, indicating potential dilution of control. Foreign Institutional Investors (FIIs) hold a modest 1.97%, suggesting limited foreign interest, which may impact investor confidence. Public ownership has risen to 53.23%, indicating a growing retail investor base, with the number of shareholders recorded at 15,796. This increase in public participation could be seen as a positive sign of confidence in the company’s potential. However, the declining stake of promoters from above 50% to the current level could raise concerns about management commitment. The gradual decline in FII participation might also reflect cautious sentiment towards the company’s operational challenges and profitability metrics, which could influence future investment decisions.
Outlook, Risks, and Final Insight
If Aarey Drugs can stabilize its revenue and improve profitability metrics, particularly its operating margins, it may enhance overall investor confidence. The company faces significant risks, including fluctuating sales and inconsistent profitability, which could hinder growth prospects. Additionally, the reliance on a limited base of institutional investors poses a risk to share liquidity and market perception. If the company can effectively manage its operational expenses and leverage its balance sheet strength, it may be positioned to exploit growth opportunities in the pharmaceutical sector. However, sustaining improvements in margins and increasing FII interest will be crucial for enhancing the company’s market position and attracting further investment. The path ahead necessitates strategic initiatives to bolster sales consistency and operational efficiency to capitalize on its existing strengths.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Aarey Drugs & Pharmaceuticals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 247/84.3 | 34.4 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,993 Cr. | 458 | 465/192 | 112 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 38.1 Cr. | 51.3 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 29.9 Cr. | 20.4 | 29.1/17.0 | 31.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,038.24 Cr | 1,197.65 | 50.64 | 194.07 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 118.84 | 76.26 | 62.47 | 162.88 | 50.96 | 57.83 | 76.48 | 210.35 | 126.91 | 105.14 | 133.79 | 108.10 | 102.21 |
| Expenses | 117.93 | 71.99 | 60.94 | 160.36 | 49.62 | 55.99 | 73.78 | 211.79 | 125.73 | 101.42 | 131.59 | 112.31 | 100.50 |
| Operating Profit | 0.91 | 4.27 | 1.53 | 2.52 | 1.34 | 1.84 | 2.70 | -1.44 | 1.18 | 3.72 | 2.20 | -4.21 | 1.71 |
| OPM % | 0.77% | 5.60% | 2.45% | 1.55% | 2.63% | 3.18% | 3.53% | -0.68% | 0.93% | 3.54% | 1.64% | -3.89% | 1.67% |
| Other Income | 0.85 | -0.94 | 0.48 | 0.84 | 0.70 | 0.84 | 0.29 | 5.14 | 1.58 | 0.02 | 0.68 | 7.54 | 1.55 |
| Interest | 0.55 | 0.59 | 0.71 | 0.20 | 0.42 | 0.41 | 0.47 | 0.40 | 0.96 | 0.49 | 0.58 | 1.30 | 1.04 |
| Depreciation | 0.41 | 0.42 | 0.55 | 1.02 | 0.89 | 1.27 | 1.06 | 1.15 | 0.47 | 1.51 | 0.90 | 0.41 | 0.49 |
| Profit before tax | 0.80 | 2.32 | 0.75 | 2.14 | 0.73 | 1.00 | 1.46 | 2.15 | 1.33 | 1.74 | 1.40 | 1.62 | 1.73 |
| Tax % | 0.00% | 9.05% | -33.33% | 83.18% | 0.00% | -22.00% | 30.14% | -0.47% | 6.77% | 8.62% | 48.57% | 71.60% | 20.81% |
| Net Profit | 0.80 | 2.12 | 1.00 | 0.36 | 0.72 | 1.23 | 1.02 | 2.15 | 1.24 | 1.60 | 0.72 | 0.47 | 1.37 |
| EPS in Rs | 0.32 | 0.84 | 0.39 | 0.14 | 0.28 | 0.48 | 0.40 | 0.77 | 0.44 | 0.57 | 0.25 | 0.17 | 0.48 |
Last Updated: August 20, 2025, 12:50 am
Below is a detailed analysis of the quarterly data for Aarey Drugs & Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 102.21 Cr.. The value appears to be declining and may need further review. It has decreased from 108.10 Cr. (Mar 2025) to 102.21 Cr., marking a decrease of 5.89 Cr..
- For Expenses, as of Jun 2025, the value is 100.50 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 112.31 Cr. (Mar 2025) to 100.50 Cr., marking a decrease of 11.81 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.71 Cr.. The value appears strong and on an upward trend. It has increased from -4.21 Cr. (Mar 2025) to 1.71 Cr., marking an increase of 5.92 Cr..
- For OPM %, as of Jun 2025, the value is 1.67%. The value appears strong and on an upward trend. It has increased from -3.89% (Mar 2025) to 1.67%, marking an increase of 5.56%.
- For Other Income, as of Jun 2025, the value is 1.55 Cr.. The value appears to be declining and may need further review. It has decreased from 7.54 Cr. (Mar 2025) to 1.55 Cr., marking a decrease of 5.99 Cr..
- For Interest, as of Jun 2025, the value is 1.04 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.30 Cr. (Mar 2025) to 1.04 Cr., marking a decrease of 0.26 Cr..
- For Depreciation, as of Jun 2025, the value is 0.49 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.41 Cr. (Mar 2025) to 0.49 Cr., marking an increase of 0.08 Cr..
- For Profit before tax, as of Jun 2025, the value is 1.73 Cr.. The value appears strong and on an upward trend. It has increased from 1.62 Cr. (Mar 2025) to 1.73 Cr., marking an increase of 0.11 Cr..
- For Tax %, as of Jun 2025, the value is 20.81%. The value appears to be improving (decreasing) as expected. It has decreased from 71.60% (Mar 2025) to 20.81%, marking a decrease of 50.79%.
- For Net Profit, as of Jun 2025, the value is 1.37 Cr.. The value appears strong and on an upward trend. It has increased from 0.47 Cr. (Mar 2025) to 1.37 Cr., marking an increase of 0.90 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.48. The value appears strong and on an upward trend. It has increased from 0.17 (Mar 2025) to 0.48, marking an increase of 0.31.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:05 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 200 | 213 | 246 | 396 | 349 | 354 | 298 | 348 | 493 | 419 | 396 | 474 | 449 |
| Expenses | 198 | 212 | 245 | 386 | 342 | 347 | 294 | 344 | 481 | 411 | 391 | 471 | 446 |
| Operating Profit | 1 | 1 | 1 | 10 | 8 | 8 | 3 | 5 | 11 | 8 | 4 | 3 | 3 |
| OPM % | 1% | 1% | 0% | 2% | 2% | 2% | 1% | 1% | 2% | 2% | 1% | 1% | 1% |
| Other Income | 2 | 3 | 3 | 3 | 3 | 4 | 7 | 7 | 3 | 3 | 7 | 10 | 10 |
| Interest | 1 | 1 | 2 | 4 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 |
| Profit before tax | 1 | 1 | 2 | 8 | 8 | 9 | 7 | 8 | 10 | 6 | 5 | 6 | 6 |
| Tax % | 22% | 23% | 29% | 31% | 25% | 27% | 20% | 21% | 35% | 37% | 12% | 34% | |
| Net Profit | 1 | 1 | 1 | 5 | 6 | 7 | 6 | 7 | 7 | 4 | 5 | 4 | 4 |
| EPS in Rs | 0.62 | 0.65 | 0.77 | 3.02 | 2.64 | 2.80 | 2.48 | 2.78 | 2.58 | 1.49 | 1.67 | 1.42 | 1.47 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 4% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | 400.00% | 20.00% | 16.67% | -14.29% | 16.67% | 0.00% | -42.86% | 25.00% | -20.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 400.00% | -380.00% | -3.33% | -30.95% | 30.95% | -16.67% | -42.86% | 67.86% | -45.00% |
Aarey Drugs & Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 10% |
| 3 Years: | -1% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | -7% |
| 3 Years: | -15% |
| TTM: | -26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 16% |
| 3 Years: | 20% |
| 1 Year: | -3% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 4% |
| 3 Years: | 3% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 2:01 pm
Balance Sheet
Last Updated: October 10, 2025, 3:18 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 17 | 17 | 17 | 18 | 23 | 23 | 23 | 23 | 25 | 25 | 28 | 28 |
| Reserves | 18 | 19 | 20 | 31 | 57 | 63 | 69 | 75 | 88 | 92 | 105 | 110 |
| Borrowings | 6 | 11 | 15 | 10 | 3 | 16 | 18 | 18 | 14 | 38 | 31 | 35 |
| Other Liabilities | 67 | 69 | 74 | 83 | 86 | 43 | 84 | 116 | 117 | 136 | 139 | 117 |
| Total Liabilities | 107 | 115 | 125 | 142 | 170 | 146 | 194 | 233 | 245 | 291 | 303 | 291 |
| Fixed Assets | 4 | 6 | 8 | 12 | 12 | 12 | 12 | 14 | 14 | 14 | 13 | 16 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Other Assets | 102 | 109 | 117 | 130 | 157 | 133 | 181 | 218 | 230 | 277 | 289 | 272 |
| Total Assets | 107 | 115 | 125 | 142 | 170 | 146 | 194 | 233 | 245 | 291 | 303 | 291 |
Below is a detailed analysis of the balance sheet data for Aarey Drugs & Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 28.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 28.00 Cr..
- For Reserves, as of Mar 2025, the value is 110.00 Cr.. The value appears strong and on an upward trend. It has increased from 105.00 Cr. (Mar 2024) to 110.00 Cr., marking an increase of 5.00 Cr..
- For Borrowings, as of Mar 2025, the value is 35.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 31.00 Cr. (Mar 2024) to 35.00 Cr., marking an increase of 4.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 117.00 Cr.. The value appears to be improving (decreasing). It has decreased from 139.00 Cr. (Mar 2024) to 117.00 Cr., marking a decrease of 22.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 291.00 Cr.. The value appears to be improving (decreasing). It has decreased from 303.00 Cr. (Mar 2024) to 291.00 Cr., marking a decrease of 12.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Mar 2024) to 16.00 Cr., marking an increase of 3.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2024) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Mar 2025, the value is 272.00 Cr.. The value appears to be declining and may need further review. It has decreased from 289.00 Cr. (Mar 2024) to 272.00 Cr., marking a decrease of 17.00 Cr..
- For Total Assets, as of Mar 2025, the value is 291.00 Cr.. The value appears to be declining and may need further review. It has decreased from 303.00 Cr. (Mar 2024) to 291.00 Cr., marking a decrease of 12.00 Cr..
Notably, the Reserves (110.00 Cr.) exceed the Borrowings (35.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.00 | -10.00 | -14.00 | 0.00 | 5.00 | -8.00 | -15.00 | -13.00 | -3.00 | -30.00 | -27.00 | -32.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 119 | 114 | 108 | 75 | 100 | 109 | 118 | 170 | 101 | 165 | 170 | 103 |
| Inventory Days | 10 | 7 | 3 | 5 | 16 | 23 | 21 | 20 | 11 | 26 | 33 | 36 |
| Days Payable | 119 | 117 | 108 | 71 | 84 | 40 | 98 | 120 | 86 | 115 | 123 | 81 |
| Cash Conversion Cycle | 9 | 5 | 3 | 9 | 32 | 92 | 42 | 69 | 26 | 76 | 80 | 58 |
| Working Capital Days | 52 | 49 | 40 | 34 | 69 | 77 | 99 | 91 | 68 | 89 | 106 | 89 |
| ROCE % | 6% | 7% | 7% | 22% | 14% | 12% | 8% | 9% | 10% | 6% | 6% | 6% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.84 | 1.67 | 1.49 | 2.72 | 2.79 |
| Diluted EPS (Rs.) | 1.84 | 1.67 | 1.49 | 2.72 | 2.79 |
| Cash EPS (Rs.) | 2.13 | 2.27 | 2.11 | 3.36 | 3.18 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 49.36 | 47.33 | 46.25 | 44.77 | 42.27 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 49.36 | 47.33 | 46.25 | 44.77 | 42.27 |
| Revenue From Operations / Share (Rs.) | 168.94 | 141.02 | 165.04 | 194.09 | 148.99 |
| PBDIT / Share (Rs.) | 4.30 | 4.07 | 4.12 | 5.52 | 4.98 |
| PBIT / Share (Rs.) | 3.61 | 3.46 | 3.50 | 4.74 | 4.59 |
| PBT / Share (Rs.) | 2.17 | 1.90 | 2.37 | 3.95 | 3.55 |
| Net Profit / Share (Rs.) | 1.43 | 1.67 | 1.49 | 2.58 | 2.79 |
| PBDIT Margin (%) | 2.54 | 2.88 | 2.49 | 2.84 | 3.34 |
| PBIT Margin (%) | 2.13 | 2.45 | 2.11 | 2.44 | 3.08 |
| PBT Margin (%) | 1.28 | 1.35 | 1.43 | 2.03 | 2.38 |
| Net Profit Margin (%) | 0.84 | 1.18 | 0.90 | 1.32 | 1.86 |
| Return on Networth / Equity (%) | 2.90 | 3.52 | 3.21 | 5.75 | 6.58 |
| Return on Capital Employeed (%) | 7.15 | 7.10 | 7.20 | 10.44 | 10.68 |
| Return On Assets (%) | 1.68 | 1.54 | 1.29 | 2.66 | 2.79 |
| Long Term Debt / Equity (X) | 0.01 | 0.02 | 0.03 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.25 | 0.23 | 0.32 | 0.12 | 0.18 |
| Asset Turnover Ratio (%) | 1.75 | 1.33 | 1.56 | 2.06 | 1.63 |
| Current Ratio (X) | 2.20 | 1.70 | 1.61 | 1.74 | 1.65 |
| Quick Ratio (X) | 1.73 | 1.49 | 1.44 | 1.63 | 1.51 |
| Inventory Turnover Ratio (X) | 11.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 3.00 | 2.61 | 3.65 | 7.01 | 4.79 |
| Interest Coverage Ratio (Post Tax) (X) | 2.00 | 2.07 | 2.32 | 4.27 | 3.68 |
| Enterprise Value (Cr.) | 127.95 | 155.10 | 97.10 | 119.06 | 71.62 |
| EV / Net Operating Revenue (X) | 0.26 | 0.39 | 0.23 | 0.24 | 0.20 |
| EV / EBITDA (X) | 10.61 | 13.59 | 9.29 | 8.50 | 6.15 |
| MarketCap / Net Operating Revenue (X) | 0.19 | 0.31 | 0.14 | 0.21 | 0.15 |
| Price / BV (X) | 0.68 | 0.94 | 0.51 | 0.92 | 0.54 |
| Price / Net Operating Revenue (X) | 0.19 | 0.31 | 0.14 | 0.21 | 0.15 |
| EarningsYield | 0.04 | 0.03 | 0.06 | 0.06 | 0.12 |
After reviewing the key financial ratios for Aarey Drugs & Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.84. This value is below the healthy minimum of 5. It has increased from 1.67 (Mar 24) to 1.84, marking an increase of 0.17.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.84. This value is below the healthy minimum of 5. It has increased from 1.67 (Mar 24) to 1.84, marking an increase of 0.17.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.13. This value is below the healthy minimum of 3. It has decreased from 2.27 (Mar 24) to 2.13, marking a decrease of 0.14.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 49.36. It has increased from 47.33 (Mar 24) to 49.36, marking an increase of 2.03.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 49.36. It has increased from 47.33 (Mar 24) to 49.36, marking an increase of 2.03.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 168.94. It has increased from 141.02 (Mar 24) to 168.94, marking an increase of 27.92.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 4.30. This value is within the healthy range. It has increased from 4.07 (Mar 24) to 4.30, marking an increase of 0.23.
- For PBIT / Share (Rs.), as of Mar 25, the value is 3.61. This value is within the healthy range. It has increased from 3.46 (Mar 24) to 3.61, marking an increase of 0.15.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.17. This value is within the healthy range. It has increased from 1.90 (Mar 24) to 2.17, marking an increase of 0.27.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 2. It has decreased from 1.67 (Mar 24) to 1.43, marking a decrease of 0.24.
- For PBDIT Margin (%), as of Mar 25, the value is 2.54. This value is below the healthy minimum of 10. It has decreased from 2.88 (Mar 24) to 2.54, marking a decrease of 0.34.
- For PBIT Margin (%), as of Mar 25, the value is 2.13. This value is below the healthy minimum of 10. It has decreased from 2.45 (Mar 24) to 2.13, marking a decrease of 0.32.
- For PBT Margin (%), as of Mar 25, the value is 1.28. This value is below the healthy minimum of 10. It has decreased from 1.35 (Mar 24) to 1.28, marking a decrease of 0.07.
- For Net Profit Margin (%), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 5. It has decreased from 1.18 (Mar 24) to 0.84, marking a decrease of 0.34.
- For Return on Networth / Equity (%), as of Mar 25, the value is 2.90. This value is below the healthy minimum of 15. It has decreased from 3.52 (Mar 24) to 2.90, marking a decrease of 0.62.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.15. This value is below the healthy minimum of 10. It has increased from 7.10 (Mar 24) to 7.15, marking an increase of 0.05.
- For Return On Assets (%), as of Mar 25, the value is 1.68. This value is below the healthy minimum of 5. It has increased from 1.54 (Mar 24) to 1.68, marking an increase of 0.14.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.25. This value is within the healthy range. It has increased from 0.23 (Mar 24) to 0.25, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.75. It has increased from 1.33 (Mar 24) to 1.75, marking an increase of 0.42.
- For Current Ratio (X), as of Mar 25, the value is 2.20. This value is within the healthy range. It has increased from 1.70 (Mar 24) to 2.20, marking an increase of 0.50.
- For Quick Ratio (X), as of Mar 25, the value is 1.73. This value is within the healthy range. It has increased from 1.49 (Mar 24) to 1.73, marking an increase of 0.24.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 11.80. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 11.80, marking an increase of 11.80.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.00. This value is within the healthy range. It has increased from 2.61 (Mar 24) to 3.00, marking an increase of 0.39.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.00. This value is below the healthy minimum of 3. It has decreased from 2.07 (Mar 24) to 2.00, marking a decrease of 0.07.
- For Enterprise Value (Cr.), as of Mar 25, the value is 127.95. It has decreased from 155.10 (Mar 24) to 127.95, marking a decrease of 27.15.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.26. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.26, marking a decrease of 0.13.
- For EV / EBITDA (X), as of Mar 25, the value is 10.61. This value is within the healthy range. It has decreased from 13.59 (Mar 24) to 10.61, marking a decrease of 2.98.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 1. It has decreased from 0.31 (Mar 24) to 0.19, marking a decrease of 0.12.
- For Price / BV (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has decreased from 0.94 (Mar 24) to 0.68, marking a decrease of 0.26.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 1. It has decreased from 0.31 (Mar 24) to 0.19, marking a decrease of 0.12.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aarey Drugs & Pharmaceuticals Ltd:
- Net Profit Margin: 0.84%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.15% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 2.9% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.73
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 60.7 (Industry average Stock P/E: 50.64)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.25
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.84%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | E-34, M.I.D.C., Thane Maharashtra 401506 | investorgrievance@aareydrugs.com http://www.aareydrugs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mihir R Ghatalia | Chairman & Managing Director |
| Mr. Nimit Rajesh Ghatalia | Executive Director |
| Ms. Bina Rajesh Ghatalia | Woman Director |
| Mr. Lalit Radhakrishna Tulsiani | Independent Director |
| Mr. Anil Mandal | Independent Director |
| Mr. Chetan K Mehta | Independent Director |
FAQ
What is the intrinsic value of Aarey Drugs & Pharmaceuticals Ltd?
Aarey Drugs & Pharmaceuticals Ltd's intrinsic value (as of 24 October 2025) is 71.55 which is 19.61% lower the current market price of 89.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 252 Cr. market cap, FY2025-2026 high/low of 89.8/31.3, reserves of ₹110 Cr, and liabilities of 291 Cr.
What is the Market Cap of Aarey Drugs & Pharmaceuticals Ltd?
The Market Cap of Aarey Drugs & Pharmaceuticals Ltd is 252 Cr..
What is the current Stock Price of Aarey Drugs & Pharmaceuticals Ltd as on 24 October 2025?
The current stock price of Aarey Drugs & Pharmaceuticals Ltd as on 24 October 2025 is 89.0.
What is the High / Low of Aarey Drugs & Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aarey Drugs & Pharmaceuticals Ltd stocks is 89.8/31.3.
What is the Stock P/E of Aarey Drugs & Pharmaceuticals Ltd?
The Stock P/E of Aarey Drugs & Pharmaceuticals Ltd is 60.7.
What is the Book Value of Aarey Drugs & Pharmaceuticals Ltd?
The Book Value of Aarey Drugs & Pharmaceuticals Ltd is 48.8.
What is the Dividend Yield of Aarey Drugs & Pharmaceuticals Ltd?
The Dividend Yield of Aarey Drugs & Pharmaceuticals Ltd is 0.00 %.
What is the ROCE of Aarey Drugs & Pharmaceuticals Ltd?
The ROCE of Aarey Drugs & Pharmaceuticals Ltd is 6.38 %.
What is the ROE of Aarey Drugs & Pharmaceuticals Ltd?
The ROE of Aarey Drugs & Pharmaceuticals Ltd is 2.96 %.
What is the Face Value of Aarey Drugs & Pharmaceuticals Ltd?
The Face Value of Aarey Drugs & Pharmaceuticals Ltd is 10.0.